Suchergebnisse - "Menter, Alan"

PubPharm (50)

1

Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis : Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial)

enthalten in: Journal of the European Academy of Dermatology and Venereology : JEADV | 2024

von Strober, B. | Bachelez, H. | Crowley, J. | +9

2

Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures

enthalten in: Journal of the American Academy of Dermatology | 2021

von Elmets, C. | Korman, N. | Prater, E. | +29

3

Ixekizumab in the treatment of moderate-to-severe plaque psoriasis : Patient adherence, satisfaction, and preferences

enthalten in: Dermatologic therapy | 2021

von Azhar, A. | Zaayman, M. | Silfvast-Kaiser, A. | +3

4

Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients

enthalten in: Journal of the American Academy of Dermatology | 2020

von Menter, A. | Cordoro, K. | Davis, D. | +29

ErratumIn: J Am Acad Dermatol. 2020 Mar;82(3):574. - PMID 32057334

5

Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study

enthalten in: American journal of clinical dermatology | 2019

von Lebwohl, M. | Blauvelt, A. | Menter, A. | +5

6

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics

enthalten in: Journal of the American Academy of Dermatology | 2019

von Menter, A. | Strober, B. | Kaplan, D. | +29

CommentIn: J Am Acad Dermatol. 2019 Aug;81(2):e45. - PMID 30930086

7

Calcipotriene betamethasone dipropionate aerosol foam in the treatment of plaque psoriasis : a review of the literature

enthalten in: Therapeutic delivery | 2017

von Frieder, J. | Kivelevitch, D. | Menter, A.

8

Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis : Sub-Group Analysis of the PSO-ABLE Study

enthalten in: American journal of clinical dermatology | 2017

von Paul, C. | Leonardi, C. | Menter, A. | +5

ErratumIn: Am J Clin Dermatol. 2017 May 24;:. - PMID 28540589

9

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

enthalten in: The New England journal of medicine | 2017

von Papp, K. | Blauvelt, A. | Bukhalo, M. | +14

10

Reversible Posterior Leukoencephalopathy Syndrome (RPLS) in a Psoriasis Patient Treated With Ustekinumab

enthalten in: Journal of drugs in dermatology : JDD | 2017

von Dickson, L. | Menter, A.

1
2
3
4
5
Nächster »
[5]